Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jns.2017.06.027 | DOI Listing |
Mol Hum Reprod
June 2024
Center for Experimental Medicine, The Third Xiangya Hospital, Central South University, Changsha, China.
Acephalic spermatozoa syndrome (ASS) is a severe teratospermia with decaudated, decapitated, and malformed sperm, resulting in male infertility. Nuclear envelope protein SUN5 localizes to the junction between the sperm head and tail. Mutations in the SUN5 gene have been identified most frequently (33-47%) in ASS cases, and its molecular mechanism of action is yet to be explored.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
June 2024
Reproductive Medicine Department, Instituto Bernabeu, Alicante, Spain; Chair Community Medicine UMH and Health Reproductive, Miguel Hernández University, Alicante, Spain.
Inflamm Regen
February 2024
Department of Geriatrics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Background: Different neural subtypes are selectively lost in diverse neurodegenerative diseases. Huntington's disease (HD) is an inherited neurodegenerative disease characterized by motor abnormalities that primarily affect the striatum. The Huntingtin (HTT) mutation involves an expanded CAG repeat, leading to insoluble polyQ, which renders GABA medium spiny neurons (MSN) more venerable to cell death.
View Article and Find Full Text PDFEndocr Relat Cancer
March 2024
Department of Andrology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
Adrenocortical carcinoma (ACC) is a malignancy with a poor prognosis and high mortality rate. A high tumor mutational burden (TMB) has been found to be associated with poor prognosis in ACC. Thus, exploring ACC biomarkers based on TMB holds significant importance for patient risk stratification.
View Article and Find Full Text PDFAnticancer Res
December 2023
Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University, Ningxia, P.R. China
Background/aim: Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is a highly effective and valuable treatment option for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations, such as T790M. However, acquired resistance ultimately limits its clinical application. In this study, we aimed to identify potential targets for overcoming osimertinib resistance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!